化学
脂质过氧化
癌症研究
谷胱甘肽
细胞毒性
免疫原性细胞死亡
前药
DNA损伤
顺铂
癌细胞
程序性细胞死亡
GPX4
药理学
细胞内
体内
转移
细胞生长
活性氧
肿瘤微环境
谷胱甘肽过氧化物酶
氧化应激
生物化学
纳米载体
提拉帕扎明
A549电池
细胞生物学
抗氧化剂
癌症
生长抑制
毒性
血管生成
细胞保护
溶酶体
聚ADP核糖聚合酶
作者
MarMar Tuohan,Ayijiang Taledaohan,Di Zhu,Yijiang Jia,Bo Hu,Liujia Chan,Yu Lu,Yuji Wang
标识
DOI:10.1186/s12951-026-04989-9
摘要
Triple-negative breast cancer (TNBC) is an aggressive type of cancer with high metastatic potential and poor clinical outcomes. Although cisplatin remains a widely used first-line therapeutic agent, its lack of tumor selectivity and its propensity to induce severe systemic toxicity severely compromise its real-world efficacy. This study designed and synthesized a novel self-assembled flavonoid-Pt(IV) prodrug (FLP) as a multimodal therapeutic against TNBC. FLP spontaneously assembled into uniform nanospheres with a hydrodynamic diameter of 150 nm, significantly enhancing cellular uptake and tumor-targeted accumulation. FLP exhibited potent cytotoxicity with IC 50 values ranging from 3.17 to 15.90 µM, substantially outperforming DFLP and cisplatin. Upon cellular internalization, reduction of the Pt(IV) scaffold consumed intracellular glutathione (GSH), directly disrupting redox homeostasis. This GSH depletion led to the inactivation of glutathione peroxidase 4 and triggered lipid peroxidation cascades, inducing ferroptosis. Concurrently, lipid peroxidation products and intracellular components released during ferroptosis served as damage-associated molecular patterns, activating immunogenic cell death (ICD). The flavonoid moiety further amplified oxidative stress, synergizing with the GSH-depleting property of the Pt(IV) scaffold. In vivo studies in a 4T1 orthotopic breast tumor model revealed that FLP achieved a tumor growth inhibition rate of 65.93%, significantly higher than that of cisplatin (49.63%), while effectively suppressing lung metastasis. In conclusion, this work presents a carrier-free Pt(IV) nanoassembly that integrates chemotherapy with ferroptosis-associated immunogenic responses, highlighting a nanoscale strategy for enhancing platinum-based therapy in TNBC.
科研通智能强力驱动
Strongly Powered by AbleSci AI